JPRN-UMIN000016870Completed未知
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization - Intravitreal tPA and ranibizumab for type 2 choroidal neovascularization
agoya City University Graduate School of Medicine0 sites20 target enrollmentStarted: March 23, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •eyes with previous photodynamic therapy, medication for glaucoma, diabetic retinopathy, epiretinal membrane, vitreomacular traction, or high myopia (-6.0 diopters or worse)
Investigators
Similar Trials
Completed
Not Applicable
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
Recruiting
Not Applicable
vitreous surgery with intravitreal tissue plasminogen activator(t-PA)globe ruptureJPRN-UMIN000015282Okayama University Hospital30
Not yet recruiting
Not Applicable
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Corticosteroid for Macular EdemaKCT0007766Hallym University Medical Center-Kangnam188
Completed
Not Applicable
Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000013975agoya University hospital ophtalmoligy30
Active, not recruiting
Phase 2
sing panitumumab with ranibizumab injected into the eye to treat exudative age-related macular degeneratioExudative age-related macular degenerationEye DiseasesISRCTN85022211fa Eye Research Institute200